Toggle light / dark theme

Engineering researchers developed a next-generation miniature lab device that uses magnetic nano-beads to isolate minute bacterial particles that cause diseases. Using this new technology improves how clinicians isolate drug-resistant strains of bacterial infections and difficult-to-detect micro-particles such as those making up Ebola and coronaviruses.

Ke Du and Blanca Lapizco-Encinas, both faculty-researchers in Rochester Institute of Technology’s Kate Gleason College of Engineering, worked with an international team to collaborate on the design of the new system — a microfluidic device, essentially a lab-on-a-chip.

Drug-resistant bacterial infections are causing hundreds of thousands of deaths around the world every year, and this number is continuously increasing. Based on a report from the United Nations, the deaths caused by antibiotics resistance could reach to 10 million annually by 2050, Du explained.

Tesla’s mobile app is one of the key parts of the Tesla ownership experience, and yet its security is lacking an important feature — two-factor authentication.

According to CEO Elon Musk, this will change in the near future.

When asked on Twitter whether there are any updates regarding two-factor authentication for the app, Musk said it’s “coming soon” (via Teslarati).

A drug that has shown promising results against coronavirus is going to be tested in four hospitals in Israel as part of a global clinical trial involving around forty clinical centers.

The drug, Selinexor, or XPOVIO as it is currently marketed in the US, has been developed by oncology-focused pharmaceutical company Karyopharm Therapeutics. Co-founded by Israeli scientist Sharon Shacham in 2008, the company is based in the US but maintains a regional office in Israel.


XPOVIO was developed for treating patients with relapsed or refractory multiple myeloma. It is FDA approved for this purpose. However, it has the potential to be a tool to fight the coronavirus, and clinical trials are needed to assess its effectiveness, according to Anat Haas Mizrahi, Karyopharm’s Israel general manager; and Dayana Michel, its senior medical director.

“In our research, we are committed also to develop drugs for additional purposes,” Haas Mizrahi told The Jerusalem Post. “One of the studies was focused on viral diseases, and we tested the drug for several of them. When the coronavirus emerged, we decided to look into our data and information, and we realized that there was an option that could be applicable for treating COVID-19, so we started looking into it.”

Amazon is partnering with local grocery stores in India to let them sell goods through the company’s ecommerce platform. Under the “Local Shops on Amazon” program, the firm aims to bring small brick and mortar stores online.

The company said the project was in a pilot phase for the last six months with more than 5,000 stores onboard. Now, with the increasing demand for delivered groceries during the coronavirus pandemic, it has decided to formally launch the program. As a part of the launch, the Amazon is pumping ₹10 crores ($1.3 million) into this initiative.

[Read: Google Duo majorly improves low-bandwidth video quality with new codec].

Who knew there were so many “smart” ways to unlock a lock? For years companies have been trying to get people to use their phones or keypads or fobs, and now a new startup called Yeeuu Tech has thrown a bunch of methods into one device. The S1 Smart Lock packs eight different unlocking methods, and it can be fitted into most existing locks.

The S1 takes the place of an existing door handle and lock barrel. To unlock it, users can scan their fingerprint, punch in a passcode, use the app via Wi-Fi or Bluetooth, use a device with NFC, tap an included custom “badge”, give a voice command through an assistant, or use an old-fashioned mechanical key.

The fingerprint sensor is located on the top in easy thumb reach, and can apparently be read in under half a second. The system can store up to 50 different fingerprints.

After years of studies, test-firings and a survey of U.S. industry in preparation for launch of a Mars Sample Return mission in 2026, NASA has settled on a solid-fueled design for a miniature rocket with a first-of-its-kind purpose: Launching a payload from Mars for a trip back to Earth.

The small launcher is called a Mars Ascent Vehicle, or MAV. The MAV will play a key role in the Mars Sample Return mission being developed by NASA and the European Space Agency.

The first element of the Mars Sample Return mission is NASA’s Perseverance rover scheduled to depart Earth in mid-July. Perseverance will collect core samples from Martian rocks and store them in tubes for retrieval by a future rover that could launch as soon as 2026.

The first EU permits for insects as a “novel food” should be issued in mid-2020. This will end the legal uncertainty about breeding insects for human consumption in Europe. Now is the time to draw lessons from Belgium, which has served as a sandbox for the fledgling industry, about its future prospects. Are we really ready to eat insects?

Romy is an adorable little blond girl who, like all children under the age of 2½ in Belgium, goes to the crèche most weekdays. Her parents spend 20 minutes every evening preparing her lunch, carefully weighing out some carbs, freshly cooked vegetables, a protein-rich ingredient, some high-quality fat and a sprinkling of chopped herbs. It’s the recommended diet for a child her age. But unlike most of Belgium’s children, Romy gets a meal that eventually includes a teaspoon of cricket powder. In fact, she even loves to snack on some whole locusts from time to time. All this thanks to Belgian’s progressive regulatory system, which allowed a whole new sector in the Western agrifood landscape to open up here a few years ago.

In theory, Romy is well on track to help fulfil the prediction, or rather prescription, of the Food and Agriculture Organisation (FAO) for insects to become “a high-value source of animal protein for the rapidly growing world population.” But the challenges ahead are huge and Belgium, as a test ground, has gained some valuable experience. Along with a few other countries in Europe, Belgium has taken a bite at insects. But sometimes it hurts.